SUBSCRIBE
SUBSCRIBE
Annalee Armstrong headshot

Annalee Armstrong

Senior Editor
New York, NY, USA - July 4, 2022: Exterior view of the Pfizer World Headquarters in New York City. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Executive Appointments
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.
November 20, 2024
 · 
2 min read
 · 
Annalee Armstrong
Podcast
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
November 20, 2024
 · 
1 min read
 · 
Heather McKenzie
Infusion bag and injection syringe in the blue background, 3d rendering. Digital drawing.
Clinical research
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.
November 19, 2024
 · 
2 min read
 · 
Annalee Armstrong
Psychological concept. Chaotic thought process
Psychedelics
Cybin’s Small Depression Study Shows 71% Remission Rate
Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month milestone.
November 18, 2024
 · 
2 min read
 · 
Annalee Armstrong
Fall of the Ukraine Economy. Recession graph with a red arrow on the Ukraine flag. Economic decline. Decline in the economy of stock trading. Downward trends in the economy. Business.
Gene therapy
Neurogene Details Gene Therapy Complication, Sending Shares Plummeting Again
Neurogene’s shares fell by 36% as the market opened Monday morning following news that a patient experienced systemic hyperinflammatory syndrome in a Phase I/II clinical trial of Rett syndrome gene therapy NGN-401.
November 18, 2024
 · 
2 min read
 · 
Annalee Armstrong
Chinese flag with digital matrix -Innovation Concept - Digital Tech Wallpaper - 3D illustration
Weight loss
Novo’s Wegovy Launched in China at a Fraction of US Price
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine for about $193.27 for a one-month supply.
November 18, 2024
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage. Conceptual image. Businessman catching money given by a hand. In search of profit. Concept of business, economy, financial growth, promotion, following
Earnings
Bluebird Faces Cash Gap With Breakeven Point in Sight
Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a projected breakeven point before the end of 2025, with analysts worried they won’t make it.
November 15, 2024
 · 
4 min read
 · 
Annalee Armstrong
Creative process. Pop art collage. Female hand typing on retro typewriter isolated over white background. Vintage, retro 80s, 70s style. Bright colors. Copy space for ad, text
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
 · 
3 min read
 · 
Annalee Armstrong
Employee competency assessment. Collage of hands holding king and a pawn. Succession planning.
Cell Therapy
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic leukemia after Bristol Myers Squibb’s Breyanzi was approved in the indication earlier this year.
November 14, 2024
 · 
1 min read
 · 
Annalee Armstrong
Arrows on a concrete wall. Red arrow, right direction. Stairs. Leadership concept. Team. Business Finance Background
Business
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.
November 13, 2024
 · 
7 min read
 · 
Annalee Armstrong
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Bayer's office in Berlin, Germany/iStock
Earnings
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged investors to be patient as the company executes on a performance-boosting strategy outlined in March.
November 12, 2024
 · 
2 min read
 · 
Annalee Armstrong
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Earnings
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
November 12, 2024
 · 
9 min read
 · 
Annalee Armstrong
Dollars as a global currency, loan, credit, and payment concept. A hand offering 100 US dollars. Minimalist art collage
ADCs
Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work
CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But Alentis is targeting an IPO as early as 2025.
November 12, 2024
 · 
2 min read
 · 
Annalee Armstrong
Brain shaped maze. Concept image of study and brain behavior.
Schizophrenia
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.
November 11, 2024
 · 
4 min read
 · 
Annalee Armstrong
Load More